We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us


Polymedco is a manufacturer and distributor for clinical laboratory supplies, including diagnostic test kits and devi... read more Featured Products: More products

Download Mobile App

POC Myocardial Infarction Test Delivers Results in 17 Minutes

By LabMedica International staff writers
Posted on 28 Mar 2024
Print article
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians rely on the troponin blood test to guide their diagnosis. The quick delivery of troponin test results is crucial, enabling physicians to diagnose and treat patients swiftly. Traditionally, this testing has been confined to hospital central laboratories, with results taking an hour or more to be communicated to the physician. Now, a high-sensitivity cardiac troponin I (hs-cTnI-II) test approved for point-of-care (POC) use in the United States allows EDs and other acute care settings to achieve quicker and more precise diagnostic and treatment decisions than previously possible.

Polymedco’s (Cortlandt Manor, NY, USA) PATHFAST hs-cTnI-II has become the first and only hs-cTnI-II test to be cleared by the U.S. Food and Drug Administration (FDA) for POC use in the United States. With FDA clearance, the test is now available in the U.S. for application on Polymedco's PATHFAST analyzer using both whole blood and plasma patient samples. This breakthrough high-sensitivity troponin assay developed for the PATHFAST Biomarker Analyzer delivers results up to three times faster than core lab testing. The results of the PATHFAST hs-cTnI-II test should be used in conjunction with other diagnostic information, including electrocardiogram (ECG), clinical observations, and patient symptoms, to support heart attack diagnoses.

The PATHFAST POC platform provides a broad spectrum of tests that offer central lab-caliber diagnostic outcomes directly to clinicians and patients, thereby saving crucial time when assessing patients with conditions that may be life-threatening. This platform empowers critical care decisions through an extensive array of lab tests for patients potentially suffering from acute myocardial infarction, congestive heart failure, deep vein thrombosis, pulmonary embolism, and various inflammatory conditions. The PATHFAST platform can provide results in just 17 minutes at the POC, significantly enhancing the efficiency of care in urgent situations. By delivering lab-quality results within minutes at the POC, PATHFAST ensures that EDs and other acute care facilities can make prompt and accurate diagnostic and treatment choices.

"Polymedco is committed to providing the most accurate and efficient diagnostics to help overburdened Emergency Departments more effectively and efficiently respond and treat patients presenting with symptoms of a heart attack," said Polymedco CEO Doug White. “Having the diagnostic accuracy of high-sensitivity cardiac troponin at the point-of-care represents a significant advancement in cardiac care in the U.S.”

Related Links:

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article


Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Protein ‘signatures’ obtained via a blood sample can be used to predict the onset of 67 diseases (Photo courtesy of Queen Mary University of London)

Protein Signatures in Blood Can Predict Risk of Developing More Than 60 Diseases

Measuring specific proteins to diagnose conditions like heart attacks, where troponin is tested, is a well-established clinical practice. Now, new research highlights the broader potential of protein measurements... Read more


view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more


view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more


view channel
Image: The tool can improve precision oncology by accurately predicting molecular subtypes and therapy responses (Photo courtesy of Shutterstock)

Computational Tool Integrates Transcriptomic Data for Improved Breast Cancer Diagnosis and Treatment

Breast cancer is the most commonly diagnosed cancer globally, presenting in various subtypes that require precise identification for effective, personalized treatment. Traditionally, cancer subtyping has... Read more


view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.